Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Pyxis Oncology Inc(PYXS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PYXS
09/25/2026: PYXS (3-star) is currently NOT-A-BUY. Pass it for now.
Pyxis Oncology is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates and immunotherapies to address difficult-to-treat solid tumors. Its primary strength lies in its specialized platform and promising pipeline of drug candidates. The main growth story involves the successful progression of key assets through clinical trials toward potential regulatory approval. However, investors face substantial risks, including a lack of commercial revenue, significant cash burn, and the inherent uncertainty of biotechnology development. The stock is best suited for growth-oriented investors with a high risk tolerance who are willing to monitor clinical data milestones closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential based on clinical trial outcomes. |
| Momentum investor | Mixed fit | This style is conditional on positive clinical data or market uptake signals. |
| Value investor | Weak fit | The lack of earnings and revenue makes traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends as it reinvests all capital into R&D. |
| Low-risk investor | Weak fit | Biotech clinical-stage stocks are inherently volatile and high-risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical results often cause massive, rapid swings in share price. |
| Valuation risk | High | Valuations are speculative and tied to future, uncertain cash flows. |
| Competition risk (Oncology) | High | Large incumbents have massive R&D budgets that can crowd out smaller players. |
| Business quality | Medium | The company has a focused science-led mission but lacks a commercial engine. |
| Dividend income | Low / none | There is no income component to this investment. |
| Execution risk | High | Failure at any clinical trial stage can result in significant loss of value. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 282.77% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 238.55M USD | Price to earnings Ratio - | 1Y Target Price 8.67 |
Price to earnings Ratio - | 1Y Target Price 8.67 | ||
Volume (30-day avg) 829.2K shares | Beta 1.34 | 52 Weeks Range 1.03 - 5.55 | Updated Date 09/27/2026 |
52 Weeks Range 1.03 - 5.55 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.4 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biotechnology R&D | Clinical trial development of ADC and immuno-oncology therapies. | The company burns cash to create new cancer drugs and hopes for a big payout from successful trial results. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 264.67M | Price to Sales(TTM) 21.61 |
Enterprise Value 264.67M | Price to Sales(TTM) 21.61 | ||
Enterprise Value to Revenue 23.94 | Enterprise Value to EBITDA 1.09 | Shares Outstanding 83.41M | Shares Floating 49.56M |
Shares Outstanding 83.41M | Shares Floating 49.56M | ||
Percent Insiders 13.53 | Percent Institutions 42.5 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Pyxis Oncology Inc
Exchange NASDAQ | Headquarters Boston, MA, United States | ||
IPO Launch date 2021-10-08 | Interim CEO & Director Mr. Thomas Civik | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.pyxisoncology.com |
Full time employees 56 | Website https://www.pyxisoncology.com | ||
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.